Table 5 Fact box of the side-effects and benefits of CRC surveillance
From: A prospective analysis of false positive events in a National Colon Cancer Surveillance Program
Variable | Surveillance effects |
|---|---|
Resource use | |
Analysed surveillance months | 110 patients for 1884 months |
Cost per successful R0 resection (£) | 103207 |
Screening tests per R0 metastases resection | |
Carcinoembryonic antigen CEA (n) | 125 |
Chest x-ray (n) | 70 |
Liver ultrasound (n) | 52 |
Colonoscopies (n) | 30 |
Total screening tests (n) | 276 |
Total health care consultations (n) | 296 |
Benefits | |
Number of cancer recurrences detected (n) | 14 |
Probability of R0 metastasis surgery (%)* | 57% (4 of 7 metastasis surgeries) |
Side effects | |
False positive events (n) | 34 (31%) |
Probability of recurrent cancer when diagnostic check up i.e. surveillance positive predictive value | 29% |
aMean days to SCE diagnosis (SD) | 39 (35) |
Asymptomatic but incurable metastases recurrences | 3 of 14 recurrences (21%) |
Quality of life | |
aMean EQ-5D VAS score (CI) | 75.9 (74.5-77.3) |
aMean EQ-5D Index score (CI) | 0.862 (0.84-0.87) |